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Research
This study is one of a series of studies 
 investi gating health effects of perfluoro octanoic 
acid (PFOA, or C8) exposure among residents 
living near the Washington Works DuPont 
Teflon-manufacturing plant in Parkersburg, 
West Virginia, USA (Steenland et al. 2009). 
We used geographic methods to investigate 
the relationship between exposure to PFOA 
and patterns of cancer risk in the mid-Ohio 
River Valley using data from the Ohio (OH) 
and West Virginia (WV) cancer registries. 
PFOA was released into the environment via 
aerial emissions and discharged into the Ohio 
River beginning in the 1950s, resulting in the 
contamination of the local drinking water 
(Paustenbach et al. 2007; Shin et al. 2011a). 
In addition to hundreds of affected private 
drinking-water wells, six nearby public water 
districts in OH and WV were also contami-
nated (Figure 1), and monitoring data show 
that even after a drastic reduction in releases, 
PFOA contamination of drinking water per-
sisted and continued to increase in some water 
districts near the plant (Shin et al. 2012).
As part of a settlement from a large class 
action lawsuit against DuPont, the C8 Science 
Panel (2012) was established to investigate 
potential health effects resulting from PFOA 
exposure, and a 1-year cross-sectional survey 
(2005–2006) known as the C8 Health Project 
was conducted among > 69,000 residents 
with ≥ 1-year residency in public water dis-
tricts contaminated by PFOA (Frisbee et al. 
2009). Measured mean PFOA levels in public 
drinking-water supplies at the time of the sur-
vey ranged from 0.03 µg/L in Mason, WV, 
to 3.49 µg/L in Little Hocking, OH, and in 
private drinking water, PFOA was measured 
at levels of ≤ 22.1 µg/L (Shin et al. 2011a). 
The median serum PFOA level in this cross-
 sectional study population was 28.2 µg/L, 
with a range of 0.2–22,412 µg/L (Steenland 
et al. 2009). PFOA has also been detected 
in the serum of the general U.S. popula-
tion, albeit at a much lower median level of 
3.9 µg/L (Calafat et al. 2007).
PFOA is widely used because of its stain-
resistant and water-repellant properties, and 
given its persistence, it is ubiquitous in many 
indoor environments, including homes and 
workplaces (Fraser et al. 2012; Haug et al. 
2011). Animal toxicologic data links PFOA 
to pancreatic cancer (acinar cells), testicular 
cancer (Leydig cells), and liver cancer (Lau 
et al. 2007). A recent review of the epide-
miologic data concluded that more stud-
ies were needed to determine whether any 
potential health effects exist and, specifically, 
that the evidence for cancer is not conclusive 
(Steenland et al. 2010). Human data for can-
cer from two occupational cohorts are limited 
to mortality and are based on small numbers. 
One of the two cohorts showed an excess of 
kidney cancer (Leonard et al. 2008), and the 
other showed positive exposure–response 
trends for pancreatic and prostate cancer 
that were not statistically significant (Lundin 
et al. 2009). In a prospective Danish cohort 
study, plasma concentrations of background 
PFOA exposures were not associated with 
prostate, bladder, pancreatic, or liver cancer 
(Eriksen et al. 2009). A case– control study 
of Greenland Inuit women found a positive 
but not statistically significant association 
between PFOA exposure and breast cancer 
(Bonefeld-Jorgensen et al. 2011). The positive 
Address correspondence to V.M. Vieira, Program in 
Public Health, AIRB 2042, University of California, 
Irvine, Irvine, CA 92697 USA. Telephone: (949) 
824-7017. E-mail: vvieira@uci.edu
Supplemental Material is available online (http://
dx.doi.org/10.1289/ehp.1205829).
We gratefully acknowledge the staff at the West 
Virginia Cancer Registry (Office of Epidemiology 
and Prevention Services, Bureau for Public Health, 
West Virginia Department of Health and Human 
Resources, Charleston, WV) and the Ohio Cancer 
Incidence Surveillance System (OCISS), Ohio 
Department of Health (ODH), for their assistance 
with the cancer data. 
The project was supported by the C8 Class Action 
Settlement Agreement (Circuit Court of Wood 
County, WV) between DuPont and plaintiffs, which 
resulted from releases into drinking water of the 
chemical perfluoro octanoic acid (PFOA, or C8). 
Funds were administered by the Garden City Group 
(Melville, NY), which reports to the court.
OCISS is a registry participating in the National 
Program of Cancer Registries of the Centers for 
Disease Control and Prevention (CDC). Use of these 
data does not imply ODH or CDC either agrees or 
disagrees with any presentations, analyses, interpreta-
tions, or conclusions. Our work and conclusions are 
independent of either party to the C8 Class Action 
lawsuit.
The authors declare they have no actual or poten-
tial competing financial interests.
Received 28 July 2012; accepted 7 January 2013.
Perfluorooctanoic Acid Exposure and Cancer Outcomes in a Contaminated 
Community: A Geographic Analysis
Verónica M. Vieira,1,2 Kate Hoffman,1,3 Hyeong-Moo Shin,4,5 Janice M. Weinberg,6 Thomas F. Webster,1 and 
Tony Fletcher7
1Department of Environmental Health, Boston University School of Public Health, Boston, Massachusetts, USA; 2Program in Public 
Health, Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, California, USA; 3Gillings School of Global 
Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; 4School of Social Ecology, University of 
California, Irvine, Irvine, California, USA; 5Department of Public Health Sciences, University of California, Davis, Davis, California, 
USA; 6Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA; 7Department of Social and 
Environmental Health Research, London School of Hygiene and Tropical Medicine, London, United Kingdom
Background: Perfluorooctanoic acid (PFOA) has been linked to cancer in occupational mortality 
studies and animal toxicologic research.
oBjective: We investigated the relationship between PFOA exposure and cancer among residents 
living near the DuPont Teflon-manufacturing plant in Parkersburg, West Virginia (WV).
Methods: Our analyses included incident cases of 18 cancers diagnosed from 1996 through 2005 
in five Ohio (OH) counties and eight WV counties. For analyses of each cancer outcome, controls 
comprised all other cancers in the study data set except kidney, pancreatic, testicular, and liver 
cancers, which have been associated with PFOA in animal or human studies. We applied logistic 
regression models to individual-level data to calculate adjusted odds ratios (AORs) and confidence 
intervals (CIs). For the combined analysis of OH and WV data, the exposure of interest was resi-
dent water district. Within OH, geocoded addresses were integrated with a PFOA exposure model 
to examine the relationship between cancer odds and categories of estimated PFOA serum.
results: Our final data set included 7,869 OH cases and 17,238 WV cases. There was a positive 
association between kidney cancer and the very high and high serum exposure categories [AOR = 2.0 
(95% CI: 1.0, 3.9) n = 9 and 2.0 (95% CI: 1.3, 3.2) n = 22, respectively] and a null association with 
the other exposure categories compared with the unexposed. The largest AOR was for testicular cancer 
with the very high exposure category [2.8 (95% CI: 0.8, 9.2) n = 6], but there was an inverse associa-
tion with the lower exposure groups, and all estimates were imprecise because of small case numbers.
conclusions: Our results suggest that higher PFOA serum levels may be associated with testicular, 
kidney, prostate, and ovarian cancers and non-Hodgkin lymphoma. Strengths of this study include 
near-complete case ascertainment for state residents and well- characterized contrasts in predicted 
PFOA serum levels from six contaminated water supplies.
key words: C8, GIS, kidney cancer, PFOA, testicular cancer. Environ Health Perspect 
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associations were generally not consistent 
among cancer sites between studies, and for 
the remaining cancer sites reported, no asso-
ciations were observed.
The objective of this study was to investi-
gate the association between PFOA exposure 
and the odds of cancer using data from the 
OH and WV cancer registries. The present 
study included residents of PFOA-exposed 
water districts and unexposed geographic areas 
outside of the C8 Health Project area, enabling 
a comparison between populations exposed to 
varying degrees and unexposed populations 
while controlling for individual-level risk fac-
tors. Results of this geographic study com-
plement other studies being done within the 
C8 Health Project population by including a 
more complete ascertainment of cases, includ-
ing those who died prior to the 2005–2006 
survey. The weight of evidence from the com-
bination of studies within this population was 
heavily considered in the determination by the 
C8 Science Panel that there was a probable 
link between PFOA exposure and testicular 
and kidney cancers.
Methods
Study population and data. The study area 
encompasses six contaminated public water 
districts (WDs) and 13 counties in OH and 
WV that surround the Washington Works 
DuPont facility (Figure 1). Incident cancer 
cases diagnosed from 1996 through 2005 in 
the OH counties of Athens, Meigs, Gallia, 
Washington, and Morgan and the WV coun-
ties of Wood, Mason, Wirt, Putnam, Jackson, 
Pleasants, Ritchie, and Cabell were obtained 
from the OH Cancer Incidence Surveillance 
System (OCISS) and from the WV Cancer 
Registry (WVCR), respectively. The WVCR 
provided an incident cancer data set of all can-
cer types with a total of 19,716 individual 
cases. There were 10,044 (51%) male cases 
and 9,673 (49%) female cases. The OCISS 
provided us with registry data for 9,402 inci-
dent cases of all cancer types. For our analy-
ses, we were able to geocode 8,650 (92%) of 
the OH addresses at diagnosis to the street 
level and the remaining 752 (8%) at the ZIP 
code level, with little variation in these pro-
portions by cancer type. There were 4,396 
(51%) male cases and 4,254 (49%) female 
cases. The median age for both data sets was 
67 years. We excluded 745 OH cases and 
2,411 WV cases of cancer types including 
oral cavity, pharynx, esophagus, larynx, stom-
ach, and Hodgkin lymphoma with too few 
cases (< 100 OH cases, the smaller of the two 
analyses) for meaningful analysis, or that had 
not been previously investigated in relation to 
PFOA in animal toxicologic studies or occu-
pational mortality studies (Lau et al. 2007; 
Leonard et al. 2008; Steenland and Woskie 
2012). We also excluded 36 OH cases and 
67 WV cases that were diagnosed at < 15 years 
of age. Our final data set included 7,869 geo-
coded OH cases and 17,238 WV cases of 18 
cancer cate gories (i.e., bladder, brain, female 
breast, cervix, colon/rectum, kidney, leukemia, 
liver, lung, melanoma of the skin, multiple 
myeloma, non-Hodgkin lymphoma, ovary, 
pancreas, prostate, testis, thyroid, and uterus).
Based on 2010 U.S. census population 
estimates, the population of the study area 
is over 500,000, with one-third in OH and 
two-thirds in WV. Using a PFOA exposure 
model and data collected from the C8 Health 
Project, the corresponding 1995 median 
PFOA serum concentrations in the six pub-
lic WDs were previously estimated as follows: 
Little Hocking (Washington and Athens 
Counties, OH), 125 µg/L; Lubeck (Wood 
County, WV), 65.8 µg/L; Tupper Plains 
(Athens and Meigs Counties, OH), 23.9 µg/L; 
Belpre (Washington County, OH), 18.7 µg/L; 
Pomeroy (Meigs County, OH), 10.7 µg/L; and 
Mason (Mason County, WV), 5.3 µg/L (Shin 
et al. 2011b). The institutional review boards 
at the Boston University Medical Campus, 
the London School of Hygiene and Tropical 
Medicine, the OH Department of Health, and 
the WV Bureau of Health Statistics approved 
the research. This study was granted a waiver of 
informed consent.
Overview of analyses. The final data set 
included information for study area resi-
dents diagnosed with 18 different categories 
of cancer. We applied logistic regression to 
 individual-level data using registry-based can-
cer controls to calculate adjusted odds ratios 
(AORs) and confidence intervals (CIs) for each 
cancer category, with the other cancer cate-
gories excluding kidney, pancreatic, testicular, 
and liver cancers (which have been linked to 
PFOA exposure in animal and human studies 
previously) serving as controls. As a sensitiv-
ity analysis, we also performed analyses using 
a control group consisting of those persons 
with all other cancer diagnoses included in the 
data set, without exclusions. We adjusted for 
age, sex, diagnosis year, smoking status (cur-
rent, past, unknown, with never smoker as 
the reference) and insurance provider (govern-
ment-insured Medicaid, uninsured, unknown, 
with privately insured as the reference). We 
ran additional analyses stratified by sex for can-
cers with ≥ 100 cases of each sex; this included 
cancers of the bladder, colon/rectum, kidney, 
and lung, as well as melanoma of the skin 
and non-Hodgkin lymphoma. To test the 
sensitivity of results to missing smoking and 
health insurance data, we generated 10 data 
sets, with imputation of missing values using 
default predictive mean matching and logistic 
regression imputation via the “mice” library 
in R (van Buuren and Groothuis-Oudshoorn 
2011). We obtained parameter estimates by 
averaging over all 10 data sets of parameter 
estimates, and variance estimates by combining 
the between- and within- imputation variances.
For exposure assessment purposes, the 
OCISS provided addresses at diagnosis that 
we geocoded, while the WVCR provided an 
identifier for each geographic unit, which 
allowed us to assign case addresses to contami-
nated water district areas or to the unexposed 
Figure 1. Study area of 13 counties encompassing six contaminated water districts.
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group. We conducted two different analyses 
to compare the robustness of our results across 
different exposure metrics. The first analysis 
used water district of residence as the exposure 
of interest and included both OH and WV 
data. The second analysis was restricted to OH 
and took advantage of the availability of geo-
coded OH addresses at time of diagnosis. We 
used an existing PFOA exposure model (Shin 
et al. 2011a, 2011b) to estimate serum levels 
at a finer geographic resolution for different 
latency assumptions. For OH-only analyses, 
we also adjusted for race, modeled as a binary 
variable for white or non-white, which was 
provided by the OCISS, but not the WVCR 
because of confidentiality concerns. The two 
analyses are described in detail below. All sta-
tistical analyses were conducted using R 2.10.1 
(R Foundation, Vienna, Austria).
Water district analysis for OH and WV 
data. For the combined OH and WV data, we 
used residency within a contaminated water 
district area as our exposure of interest. For the 
OH data, we assigned cases to water districts 
using geocoding, the process by which mea-
sures of longitude and latitude are calculated 
for street addresses using reference street files. 
We first cleaned and standardized addresses 
using ZP4 address correction software with 
the LACS (Locatable Address Conversion 
System) database (version expiring 1 April 
2011; Semaphore Corporation, Monterey, 
CA, USA) and then converted additional rural 
route boxes to street addresses using Enhanced 
911 address conversion tables (Vieira et al. 
2010). Geocoding was then performed using 
a geographic information system (GIS), ESRI 
ArcView version 9.3 (Redlands, CA, USA) 
with the ESRI StreetMap Premium North 
America NAVTEQ 2010 enhanced street 
data set as the reference address locator. Using 
geocoding, we were able to identify cases liv-
ing within a contaminated water district area. 
Cases not in contaminated water districts were 
assigned to the unexposed group.
For WV cases, data release restrictions 
prohibited identifiable geographic location 
from being included with the cancer data. 
Instead, a variable was provided to indicate 
whether cases were located in Lubeck WD, 
Mason County WD, or unexposed areas. 
Only addresses in Wood County were geo-
coded to the water district distribution system 
at the WVCR to determine whether the case 
was living at a street address serviced by the 
Lubeck WD. Wood County cases not on the 
Lubeck WD distribution system were consid-
ered unexposed. All cases in Mason County 
were assigned exposure to the Mason County 
WD. Mason County addresses were not geo-
coded because the median PFOA serum levels 
were close to background.
We calculated AORs and CIs for each of 
the 18 cancer categories in association with one 
of the six contaminated water districts versus 
an unexposed water district. We also calculated 
the AORs for residence in any exposed water 
district relative to unexposed water districts.
Estimated PFOA serum level analysis in 
OH. To take advantage of the availability of 
geocoded street addresses in the OH data, we 
also used modeled serum PFOA concentra-
tion as an exposure metric. All OH addresses 
at time of diagnosis were geocoded to deter-
mine whether the case was serviced by one of 
the contaminated public water districts or a 
contaminated private well or was unexposed. 
This geocoding allowed us to be even more 
specific about exposure as cases living within a 
water district area, but not on a street serviced 
by a distribution pipe (or before the year of 
pipe installation), would likely be access-
ing drinking water from a private residential 
well. The methods for estimating individual 
serum PFOA levels from linked environmen-
tal, exposure, and pharmacokinetic models 
are described in detail elsewhere (Shin et al. 
2011a, 2011b). Briefly, the environmental 
models integrate facility emissions data, fate 
and transport characteristics of PFOA, and 
hydrogeological properties of the study area 
to estimate PFOA air and water concentra-
tions from 1951 through 2008. Using GIS, 
we were also able to determine what year the 
pipe that serviced each case was installed. For 
each case, annual PFOA serum levels were 
calculated from 1951 to date of diagnosis by 
linking historical air and groundwater con-
centrations to residential information at time 
of diagnosis and applying standard assump-
tions about water intake, body weights, and a 
PFOA half-life in the exposure and pharmaco-
kinetic models (Shin et al. 2011b). Because 
only the residence at diagnosis was available, 
annual serum levels were estimated assum-
ing cases lived at that address for 10 years. 
As a sensitivity analysis, we also estimated 
serum levels with and without a 10-year 
latency period prior to date of diagnosis, 
assuming a lifetime residency at that address. 
We then extracted two exposure metrics for 
each latency and residency assumption: a) the 
estimated annual serum level corresponding 
to the year of diagnosis or 10 years prior for 
latency analyses, and b) a cumulative mea-
sure summed over the corresponding years of 
exposure. The estimated annual serum level 
is equivalent to what would be measured in a 
serum sample taken during that year, whereas 
the cumulative measure is the area under the 
serum level profile curve.
We first categorized individual-level expo-
sure as very high, high, medium, low, and 
unexposed using cutoffs based on the distribu-
tion of the annual PFOA serum concentra-
tions among the exposed study population, 
assuming a 10-year residency. The distribu-
tion of estimated annual PFOA serum levels 
among the exposed study population ranged 
from 3.7 to 655 µg/L for 10-year residency, 
assuming 10-year latency [see Supplemental 
Material, Figure S1 (http://dx.doi.org/10.1289/
ehp.1205829)]. The tertile breaks of the distri-
bution defined the cutoffs for low, medium, 
and high. We used the tertile breaks of 12.9 and 
30.8 to define high (30.8–109 µg/L), medium 
(12.9–30.7 µg/L), and low exposure categories 
(3.7–12.9), with unexposed serving as the ref-
erence category. There was a large break in the 
distribution at 110 µg/L, so a very high group 
was created based on this break value that 
included the upper 10% of our exposed popu-
lation (see Supplemental Material, Figure S1). 
Cumulative exposure categories were based on 
the distribution among the exposed cases and 
were divided into the following groups: very 
high = 600–4,679 µg/L-years; high = 198–
599 µg/L-years; medium = 89–197 µg/L-years; 
and low = 3.9–88 µg/L-years. We analyzed the 
individual-level OH data using logistic regres-
sion to calculate AORs and CIs for exposure 
categories, with unexposed serving as the refer-
ent. For comparison, separate analyses were 
conducted for the annual and cumulative 
exposure measures calculated for the  different 
latency and residency assumptions.
Results
OH and WV water district analyses. Table 1 
shows the distribution of cases in the contami-
nated water district areas and the surrounding 
unexposed geographic area. The Little Hocking 
WD is the highest exposed district, followed 
by Lubeck, Tuppers Plains, Belpre, Pomeroy, 
and Mason County. The odds (AORs) of tes-
ticular cancer were increased in Little Hocking 
[5.1 (95% CI: 1.6, 15.6); n = 8], and the 
odds of kidney cancer was elevated in Little 
Hocking [1.7 (95% CI: 0.4, 3.3; n = 10)] 
and Tuppers Plains [2.0 (95% CI: 1.3, 3.1) 
n = 23]. Residents of Little Hocking also had 
increased odds of non-Hodgkin lymphoma 
[1.6 (95% CI: 0.9, 2.8) n = 14] and prostate 
cancer [1.4 (95% CI: 0.9, 2.30 n = 36].
OH serum level analyses. AORs suggested 
associations between the very high PFOA 
exposure category and several cancers, but 
AORs for lower exposure categories generally 
did not support a positive dose– response rela-
tion (Table 2). Kidney cancer was positively 
associated with very high and high exposure 
categories [2.0, (95% CI: 1.0, 3.9) n = 9 and 
2.0 (95% CI: 1.3, 3.2) n = 22, respectively], 
whereas AORs for medium and low exposure 
categories were close to the null compared 
with the unexposed. The largest AOR was for 
testicular cancer with the very high exposure 
category [2.8 (95% CI: 0.8, 9.2) n = 6] but the 
estimate was imprecise due to small numbers, 
and AORs for high, medium, or low exposure 
categories, which were based on only 1, 3, and 
1 cases, respectively, were all < 1.0. Ovarian 
PFOA exposure and cancer
Environmental Health Perspectives • volume 121 | number 3 | March 2013 321
cancer was also positively associated with the 
very high exposure category [2.1 (95% CI: 
0.8, 5.5) n = 5] but again imprecise because 
of small numbers, and weaker associations 
for the high and medium exposure catego-
ries with a negative association in the lowest 
exposure category. AORs for the association 
between the very high and medium exposure 
categories and non-Hodgkin lymphoma were 
moderate [1.8 (95% CI: 1.0, 3.4) n = 11 and 
1.5 (95% CI: 1.0, 2.2) n = 28, respectively], 
while AORs for high and low exposure cat-
egories were close to the null compared with 
the unexposed. Prostate cancer showed a weak 
but relatively precise positive association with 
very high exposure [1.5 (95% CI: 0.9, 2.5) 
n = 31] and no association with lower levels 
of exposure. Results were very similar for asso-
ciations with the cumulative exposure measure 
[see Supplemental Material, Table S1 (http://
dx.doi.org/10.1289/ehp.1205829)], and for 
exposure estimates that did not account for 
latency (see Supplemental Material, Table S2), 
which were highly correlated with estimated 
exposures that assumed a 10-year latency 
(Spearman’s rank correlation rS = 0.997, 
p < 0.001). In addition, associations were 
similar when the alternative control group 
(which included kidney, liver, pancreas, and 
testis cancer cases) was used (see Supplemental 
Material, Table S3).
To test the sensitivity of our analyses 
to missing smoking (n = 2,452) and health 
insurance data (n = 1,824), we ran multiple 
imputations for cancers of the bladder, colon/
rectum, female breast, kidney, lung, prostate 
and uterus and melanoma of the skin and non-
Hodgkin lymphoma with sufficient numbers 
(≥ 100 cases with complete covariate data) and 
we observed similar results [see Supplemental 
Material, Table S4 (http://dx.doi.org/10.1289/
ehp.1205829)].
For cancers of the bladder, colon/rectum, 
kidney, and lung and melanoma of the skin and 
non-Hodgkin lymphoma with sufficient num-
bers to stratify by sex (≥ 100 cases in men and 
women, respectively), we observed generally 
similar results with regard to PFOA exposure 
categories (data not shown). An exception was 
kidney cancer, which was positively associated 
with very high exposure in women (n = 108) 
Table 1. WV and OH water district results: n and AORs (95% CIs) for exposure to contaminated water districts.
Cancer outcome
Total Total exposed Little Hocking Lubeck Tuppers Plains Belpre Pomeroy Mason
n n AOR (CI) n AOR (CI) n AOR (CI) n AOR (CI) n AOR (CI) n AOR (CI) n AOR (CI)
Bladder 1,350 137 0.8 (0.7, 1.0) 7 0.6 (0.3, 1.4) 24 1.0 (0.6, 1.5) 20 0.9 (0.6, 1.5) 24 1.1 (0.7, 1.6) 4 0.8 (0.3, 2.1) 58 0.7 (0.6, 1.0)
Brain 506 60 1.0 (0.8, 1.3) 1 0.2 (0.0, 1.5) 7 0.8 (0.4, 1.8) 9 1.1 (0.5, 2.1) 11 1.2 (0.6, 2.2) 3 1.7 (0.5, 5.4) 29 1.1 (0.7, 1.6)
Female breast 4,057 436 1.0 (0.9, 1.1) 33 1.2 (0.8, 2.0) 69 1.2 (0.9, 1.7) 50 0.7 (0.5, 1.1) 73 1.1 (0.8, 1.5) 18 0.8 (0.5, 1.5) 193 1.0 (0.8, 1.2)
Cervix 338 35 0.8 (0.6, 1.2) 4 0.9 (0.3, 2.9) 5 0.7 (0.3, 1.7) 8 1.8 (0.8, 3.8) 5 0.6 (0.2, 1.6) 2 0.9 (0.2, 4.1) 11 0.7 (0.4, 1.3)
Colon/rectum 3,543 383 0.9 (0.8, 1.0) 20 0.7 (0.5, 1.2) 44 0.7 (0.5, 1.0) 66 1.2 (0.9, 1.6) 55 0.9 (0.7, 1.2) 18 1.2 (0.7, 2.1) 180 0.9 (0.8, 1.1)
Kidney 751 94 1.1 (0.9, 1.4) 10 1.7 (0.9, 3.3) 9 0.7 (0.4, 1.3) 23 2.0 (1.3, 3.1) 17 1.4 (0.8, 2.3) 0 — 35 0.9 (0.6, 1.3)
Leukemia 674 72 0.9 (0.7, 1.1) 5 1.0 (0.4, 2.3) 11 0.9 (0.5, 1.6) 9 0.8 (0.4, 1.7) 12 1.0 (0.6, 1.9) 1 0.4 (0.1, 2.8) 34 0.9 (0.6, 1.3)
Liver 179 23 1.1 (0.7, 1.6) 1 0.8 (0.1, 5.6) 4 1.3 (0.5, 3.5) 3 1.0 (0.3, 3.3) 3 1.0 (0.3, 3.1) 1 1.4 (0.2, 10.5) 11 1.0 (0.5, 1.9)
Lung 4,926 632 1.2 (1.1, 1.3) 37 1.0 (0.7, 1.5) 85 1.1 (0.8, 1.4) 84 1.3 (1.0, 1.7) 90 1.1 (0.9, 1.4) 23 1.1 (0.7, 1.8) 313 1.3 (1.1, 1.5)
Melanoma of the 
skin
1,428 168 0.9 (0.8, 1.1) 12 1.0 (0.6, 1.9) 32 1.2 (0.8, 1.7) 21 0.9 (0.6, 1.4) 38 1.4 (1.0, 2.0) 4 0.9 (0.3, 2.5) 61 0.7 (0.5, 0.9)
Multiple myeloma 285 36 1.1 (0.8, 1.6) 1 0.5 (0.1, 3.6) 4 0.9 (0.3, 2.3) 3 0.7 (0.2, 2.2) 7 1.5 (0.7, 3.2) 1 0.9 (0.1, 6.6) 20 1.4 (0.9, 2.2)
Non-Hodgkin 
lymphoma
1,124 152 1.2 (1.0, 1.5) 14 1.6 (0.9, 2.8) 20 1.1 (0.7, 1.7) 21 1.2 (0.8, 1.9) 24 1.3 (0.9, 2.0) 5 1.1 (0.4, 2.7) 68 1.2 (0.9, 1.5)
Ovary 417 48 1.0 (0.8, 1.4) 5 1.8 (0.7, 4.4) 5 0.7 (0.3, 1.7) 6 1.1 (0.5, 2.4) 11 1.6 (0.9, 3.0) 2 1.1 (0.3, 4.4) 19 0.9 (0.5, 1.4)
Pancreas 495 58 1.0 (0.8, 1.3) 4 1.1 (0.4, 3.0) 9 1.1 (0.6, 2.1) 10 1.3 (0.7, 2.5) 8 0.9 (0.4, 1.8) 2 1.0 (0.2, 4.1) 25 0.9 (0.6, 1.4)
Prostate 3,678 434 0.9 (0.8, 1.1) 36 1.4 (0.9, 2.3) 78 1.2 (0.9, 1.6) 56 0.8 (0.6, 1.1) 56 0.8 (0.6, 1.1) 12 1.3 (0.6, 2.6) 196 0.9 (0.7, 1.0)
Testis 134 18 1.0 (0.6, 1.8) 8 5.1 (1.6, 15.6) 2 0.9 (0.2, 4.5) 2 0.4 (0.1, 2.0) 1 0.6 (0.1, 5.0) 0 — 5 0.5 (0.2, 1.5)
Thyroid 343 40 1.1 (0.7, 1.5) 3 0.8 (0.3, 2.7) 7 1.2 (0.6, 2.6) 2 0.3 (0.1, 1.4) 5 0.9 (0.4, 2.2) 0 — 23 1.4 (0.9, 2.2)
Uterus 879 97 1.0 (0.8, 1.3) 7 1.1 (0.5, 2.4) 15 1.1 (0.6, 1.9) 12 0.9 (0.5, 1.6) 14 0.9 (0.5, 1.6) 4 0.9 (0.3, 2.4) 45 1.1 (0.8, 1.5)
Adjusted for age, sex, diagnosis year, insurance provider, and smoking status; controls were other listed cancers excluding kidney, liver, pancreas, and testis cancers. Estimated 
1995 median PFOA serum concentrations in the WDs: Little Hocking = 125 µg/L; Lubeck = 65.8 µg/L; Tupper Plains = 23.9 µg/L; Belpre = 18.7 µg/L; Pomeroy = 10.7 µg/L; and 
Mason = 5.3 µg/L; reference = unexposed.
Table 2. OH serum-level results: n and AORs (95% CIs) for individual-level annual PFOA serum exposure categories assuming 10-year residency and latency.
Cancer outcome
Total Total exposed Very high High Medium Low
n n n AOR (CI) n AOR (CI) n AOR (CI) n AOR (CI)
Bladder 395 69 4 0.6 (0.2, 1.5) 21 1.2 (0.8, 2.0) 21 0.9 (0.6, 1.4) 23 0.9 (0.6, 1.4)
Brain 150 32 0 — 4 0.6 (0.2, 1.6) 16 1.8 (1.1, 3.2) 12 1.5 (0.8, 2.7)
Female breast 1,260 223 29 1.4 (0.9, 2.3) 45 0.7 (0.5, 1.0) 77 1.1 (0.8, 1.5) 72 0.9 (0.7, 1.2)
Cervix 144 25 2 0.6 (0.1, 2.6) 8 1.7 (0.8, 3.8) 4 0.5 (0.2, 1.5) 11 1.1 (0.6, 2.2)
Colon/rectum 1,149 212 13 0.6 (0.3, 1.0) 63 1.3 (1.0, 1.7) 64 0.9 (0.7, 1.2) 72 1.0 (0.8, 1.3)
Kidney 246 59 9 2.0 (1.0, 3.9) 22 2.0 (1.3, 3.2) 17 1.2 (0.7, 2.0) 11 0.8 (0.4, 1.5)
Leukemia 191 36 2 0.6 (0.1, 2.3) 8 0.9 (0.4, 1.8) 12 1.0 (0.6, 1.9) 14 1.2 (0.7, 2.1)
Liver 61 11 0 — 3 1.0 (0.3, 3.1) 4 0.9 (0.3, 2.5) 4 1.1 (0.4, 3.1)
Lung 1,526 293 29 1.0 (0.7, 1.6) 78 1.2 (0.9, 1.6) 95 1.0 (0.8, 1.3) 91 1.0 (0.7, 1.2)
Melanoma of the skin 429 95 9 0.9 (0.5, 1.9) 21 1.0 (0.6, 1.5) 38 1.3 (0.9, 1.8) 27 1.2 (0.8, 1.8)
Multiple myeloma 83 18 1 0.6 (0.1, 4.7) 4 1.0 (0.3, 2.7) 6 1.1 (0.5, 2.6) 7 1.4 (0.7, 3.2)
Non-Hodgkin lymphoma 347 76 11 1.8 (1.0, 3.4) 17 1.1 (0.7, 1.9) 28 1.5 (1.0, 2.2) 20 1.0 (0.6, 1.6)
Ovary 128 27 5 2.1 (0.8, 5.5) 8 1.4 (0.7, 2.9) 10 1.4 (0.7, 2.7) 4 0.5 (0.2, 1.4)
Pancreas 162 33 2 0.6 (0.1, 2.5) 9 1.1 (0.6, 2.3) 10 0.9 (0.5, 1.7) 12 1.3 (0.7, 2.3)
Prostate 1,155 214 31 1.5 (0.9, 2.5) 47 0.8 (0.5, 1.1) 65 0.8 (0.6, 1.0) 71 1.1 (0.8, 1.5)
Testis 61 11 6 2.8 (0.8, 9.2) 1 0.3 (0.0, 2.7) 3 0.6 (0.2, 2.2) 1 0.2 (0.0, 1.6)
Thyroid 94 15 2 0.8 (0.2, 3.5) 3 0.7 (0.2, 2.1) 5 0.9 (0.4, 2.3) 5 0.9 (0.4, 2.3)
Uterus 288 47 4 0.7 (0.3, 1.5) 12 1.7 (1.2, 2.5) 14 0.9 (0.6, 1.3) 17 1.2 (0.8, 1.7)
Adjusted for age, race, sex, diagnosis year, insurance provider, and smoking status; controls were other listed cancers excluding kidney, liver, pancreas, and testis cancers.  Categories 
of modeled PFOA serum concentrations: very high = 110–655 µg/L; high = 30.8–109 µg/L; medium = 12.9–30.7 µg/L; low = 3.7–12.8 µg/L; reference = unexposed.
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[AOR = 3.5 (95% CI: 1.4, 8.3) n = 6] but not 
men (n = 138) [AOR = 1.0 (95% CI: 0.3, 3.4) 
n = 3] compared with the unexposed.
Discussion
Testicular cancer was positively associated with 
the highest PFOA water district [AOR = 5.1 
(95% CI: 1.6, 15.6) n = 8] and the high-
est serum exposure category [AOR = 2.8 
(95% CI: 0.8, 9.2) n = 6] compared with cases 
living in unexposed areas. However, we also 
observed an inverse association between testi-
cular cancer and the lower exposure groups, 
and all of the estimates were imprecise because 
of small numbers of cases. Evidence of effects 
of PFOA on testicular Leydig cell tumors in 
animal models has been reported (Lau et al. 
2007). Kidney cancer was increased in asso-
ciation with both high and very high PFOA 
exposure, based on larger numbers of cases. 
We also observed elevated AORs for very high 
PFOA exposure and ovarian [2.0 (95% CI: 
0.8, 5.1) n = 5] and prostate [1.5 (95% CI: 
1.0, 2.5) n = 31] cancers and non-Hodgkin 
lymphoma [1.8 (95% CI: 0.9, 3.3) n = 11].
A limitation of our study is that we used 
other types of cancer as our controls (referents). 
In our analysis we assumed that referent can-
cers were not associated with exposure to 
PFOA. For our main analyses we excluded 
kidney, pancreatic, testicular, and liver cancers 
from controls because these cancers have been 
linked to PFOA exposure in animal or human 
studies previously; however, analyses using all 
other cancers as referents were comparable. We 
further assumed that different types of cancer 
were ascertained by the registry in the same 
way, and that they were sampled from the same 
source population.
Despite the large overall sample size of 
our study, the water district analyses and the 
analyses of the very high exposure group were 
limited by small numbers of many individual 
cancer cases. There was also little consistency 
in the results across exposure categories, with 
no evidence of a positive dose response. We 
were further limited by the covariates we could 
adjust for, which included only age, sex, race 
(white or non-white, OH only), smoking sta-
tus, and health insurance provider. We were 
therefore unable to adjust for other risk factors 
of potential interest (e.g., prenatal exposure to 
xenoestrogens in relation to testicular cancer) 
although such factors would also have to have 
been associated with exposure to cause con-
founding. Chance is also a concern because we 
are investigating multiple cancer sites.
As expected under the assumption that 
a positive association is truly present, we 
observed similar but weaker associations for 
most outcomes when no latency was assumed. 
Because exposure in our study was depen-
dent on location and the ranking of exposure 
between districts generally remained stable 
over time, there was very little movement of 
cases across exposure categories with respect to 
latency assumptions. As a sensitivity analy sis, 
we also modeled exposures assuming the cases 
lived at their residences their entire lifetimes 
and observed similar results [see Supplemental 
Mater ia l s ,  Table  S4  (ht tp : / /dx .doi .
org/10.1289/ehp.1205829)]. However, both 
the latency and residential history measures 
were highly correlated (Spearman’s rank cor-
relations: rS > 0.99, p < 0.001). Moving within 
the same public water district would also have 
little or no impact on the estimated serum 
values, but moving across water districts, or 
especially from more distant locations, could 
lead to exposure misclassification. Based on 
data from the C8 Health Project for residents 
> 50 years of age, the median residency dura-
tion for their current residence in 2005–2006 
was 17 years. Therefore, we felt the 10-year 
residency duration with a 10-year latency was 
a reasonable assumption. Any resulting expo-
sure misclassi fi cation is likely nondifferential, 
so the bias in the highest exposure category 
should, on average, be toward the null.
Strengths of our study include a relatively 
large overall sample size, ascertainment of cases 
from cancer registries using controls from the 
same population as the cases, good success 
in geocoding of OH residences, and use of a 
validated exposure model for predicting serum 
levels. Previous work has shown that the corre-
lation between measured and predicted serum 
in 2005–2006 using this exposure model was 
0.82 (Shin et al. 2011b). Water and serum 
concentrations in the more exposed areas were 
well above background, providing a larger 
exposure contrast compared with other cancer 
studies of PFOA in general populations. We 
found qualitatively similar results for testicu-
lar, kidney, ovarian and prostate cancers and 
non-Hodgkin lymphoma using the two differ-
ent analyses; the robustness of these results is 
another strength.
Both analyses used individual-level out-
come and risk factor information, but the first 
analysis used a group-level water district expo-
sure measure so that both OH and WV data 
could be analyzed together. The second analysis 
used estimates of serum PFOA as the exposure 
of interest, allowing us to use geocoded resi-
dences to estimate exposure metrics based on 
points in time or cumulative measures, but 
only for OH cases. The second analysis had 
the advantages of being a fully individual-level 
design [eliminating the possible semi-ecologic 
bias of the other analysis (Webster 2007)] and 
using an exposure model previously validated 
as a predictor of serum levels in this context. 
However, there was still a potential for expo-
sure misclassification in using residence at diag-
nosis. A disadvantage is that we were able to 
analyze only OH data because geocoded resi-
dences were not available for WV.
Associations between PFOA exposures and 
the same cancers have been reported in other 
unpublished C8 Science Panel (2012) studies 
of the same community. Interviews of 32,254 
adult community residents and DuPont work-
ers were conducted in 2008–20011, and 
medi cal records were sought. Cox regression of 
hazard ratios of medically validated cancers in 
relation to modeled cumulative PFOA serum 
levels at dates of diagnoses indicated increas-
ing kidney cancer risk with increasing expo-
sure when latency was not considered. When 
10-year latency was included in the exposure 
metric, the association was less evident. The 
relative risks (RRs) for testicular cancer in 
relation to increasing exposure quartiles with 
10-year latency were 1.0, 1.2, 1.7, and 3.0. 
Cross-sectional analysis of preva lent cancers 
among 49,082 adult community members 
interviewed in 2005–2006 in relation to mea-
sured PFOA indicated increased RRs with 
increased serum PFOA quartiles compared 
with the lowest quartile (RRs = 1.0, 1.5, 1.7, 
and 1.7, respectively).
Conclusions
The geographic analyses of cancer regis-
try data provide some evidence that higher 
PFOA serum levels may be associated with 
certain cancers. The association in the highest 
PFOA exposure group was largest but very 
imprecise for testicular cancer, and smaller but 
more precise for kidney cancer. Non-Hodgkin 
lymphoma and ovarian and prostate cancers 
were associated with very high exposure based 
on some models, but there was little or no 
evidence of associations with other cancers. 
Analyses were limited by a case-only design 
with minimal control of confounders and by 
small case numbers despite having 10 years of 
data. In addition, residential history informa-
tion was not available to account for latency, 
migration, and other issues regarding timing 
of exposure relative to cancer. However, the 
registries cover all residents in the study area, 
which comprises water districts with large, 
known contrasts in contamination. Thus, our 
geographic analyses using cancer registry data 
contributes to the evidence for the conclusion 
of the C8 Science Panel (2012) of a probable 
link between PFOA exposure and testicular 
and kidney cancers.
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